45 results
8-K
EX-1.1
ANNX
Annexon, Inc.
7 Jun 24
Annexon Announces Pricing of $125 Million Underwritten Public Offering
4:42pm
such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither … , and to the Company’s knowledge, no such notices are threatened or pending; (ii) is currently conducting or paying for, in whole or in part, any investigation
8-K
EX-99.2
ANNX
Annexon, Inc.
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). These are currently limited by federal law
8-K
EX-99.1
5w7dfgo4gyzddw
4 Mar 24
Regulation FD Disclosure
5:25pm
8-K
EX-4.1
87tz68y ftmbbb9m
21 Dec 23
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
4:09pm
8-K
EX-1.1
ke1dqi yybu
21 Dec 23
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
4:09pm
8-K
EX-10.1
ahhrjvp4cxtnrzp ygz
8 Jul 22
Annexon Announces $130 Million Private Placement Financing
5:19pm
8-K
EX-4.1
hh5azpm7
8 Jul 22
Annexon Announces $130 Million Private Placement Financing
5:19pm
8-K
EX-4.2
bvgcvnb
8 Jul 22
Annexon Announces $130 Million Private Placement Financing
5:19pm
8-K
EX-99.2
364xp
8 Jul 22
Annexon Announces $130 Million Private Placement Financing
5:19pm